Silence Therapeutics Plc American Depository Share (SLN)
SLN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/0001193125-26-092591-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SLN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001479615 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $559K |
| Net income | -$88.6M |
| Operating income | -$91.1M |
| Net margin | -15851.9% |
| Operating margin | -16292.8% |
| Revenue growth | -98.7% |
| Cash | $11.3M |
| Total assets | $131.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2201.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "As of September 30, 2026, the Group had cash and cash equivalents of $ 247.7 million. 9 Silence Therapeutics plc Notes to the Condensed Consolidated Financial Statements (Unaudited) - ( Continued ) In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of financial statements: Going concern, the Group has the responsibility to evaluate whether conditions and/or events raise substantial doub" | 10-Q 2026-11-13 |
| Cash and burn | $247.7M cash; operating cash flow -$11.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 62,203,024 (2026-09-30); 47,233,949 a year earlier; 39,615,655 three years earlier. | Cover page 2026-09-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-08-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Reading, United Kingdom | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$12.4M | -$12.8M | $247.7M | No debt tags | $456K | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $0 | -$12.3M | $1.5M | $72.1M | No debt tags | $615K | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $422K | -$15.0M | -$15.6M | $5.7M | No debt tags | $839K | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $34K | -$11.8M | -$17.3M | $11.3M | No debt tags | $559K | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $159K | -$21.0M | -$10.9M | $82.0M | No debt tags | $25.8M | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | $224K | -$27.4M | -$21.8M | $41.7M | No debt tags | $27.2M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $142K | -$28.5M | -$12.3M | $64.9M | No debt tags | $27.7M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $25.3M | $12.3M | -$27.5M | $121.3M | No debt tags | $43.3M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-11-12 |
Source: SEC EDGAR submissions feed, 280 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | +123.6% |
| 3 months | +41.9% |
| Year to date | +226.2% |
| 1 year | +186.6% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AAPG | Ascentage Pharma Group International American Depository Shares | $13.29 | -9.10% | $1.2B |
| AMPH | Amphastar Pharmaceuticals Inc. | $29.17 | -0.68% | $1.2B |
| NKTR | Nektar Therapeutics | $36.44 | -2.23% | $1.2B |
| OMER | Omeros Corporation | $16.68 | -4.63% | $1.2B |
| OPK | OPKO Health Inc. | $1.62 | -3.57% | $1.2B |
| KARD | Kardigan Inc. | $12.85 | -7.02% | $1.2B |
| MNKD | MannKind Corporation | $3.96 | -4.24% | $1.3B |
| GHRS | GH Research PLC | $18.75 | -1.83% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier